Fig. 6: A model depicting the proposed mechanism by which SAPCD2 promotes NB progression.
From: SAPCD2 promotes neuroblastoma progression by altering the subcellular distribution of E2F7
(Left) SAPCD2 binds to E2F7 in the cytoplasm and thereby alters the subcellular distribution of E2F7, derepressing E2F signaling transactivation, and promoting NB progression. XPO1 mediates the nuclear export of E2F7 in NB cells. (Right) GSK-J4 treatment reduces the level of SAPCD2 in NB cells and limits the binding of SAPCD2 to E2F7 in the cytoplasm. Selinexor inhibits the XPO1-dependent nuclear export of E2F7. Nuclear accumulation of E2F7 inhibits the E2F signaling and suppresses the progression of NB cells.
